There's no sugar-coating it: GlaxoSmithKline (GSK +2.23%) had a pretty rough second quarter. U.S. sales of aging blockbuster Advair dropped by an astounding 19%, and Breo and Anora Ellipta, which have been hailed as potential blockbusters, turned in disappointing sales (5 million pounds each in the U.S.). Watch the video below for a quick take on earnings from Motley Fool health care analysts Michael Douglass and David Williamson.
It was a rough quarter for GlaxoSmithKline. Were there any silver linings?
About the Author
Former Deputy Managing Editor, Fool.com. I started in Healthcare, but you'll find me writing regularly about biotech, dividend stocks, and personal finance.